Skip to main content
Top
Published in: Journal of Cardiovascular Magnetic Resonance 1/2019

Open Access 01-12-2019 | Magnetic Resonance Imaging | Research

Comparison of myocardial fibrosis quantification methods by cardiovascular magnetic resonance imaging for risk stratification of patients with suspected myocarditis

Authors: Christoph Gräni, Christian Eichhorn, Loïc Bière, Kyoichi Kaneko, Venkatesh L. Murthy, Vikram Agarwal, Ayaz Aghayev, Michael Steigner, Ron Blankstein, Michael Jerosch-Herold, Raymond Y. Kwong

Published in: Journal of Cardiovascular Magnetic Resonance | Issue 1/2019

Login to get access

Abstract

Background

Although the presence of late gadolinium enhancement (LGE) using cardiovascular magnetic resonance imaging (CMR) is a significant discriminator of events in patients with suspected myocarditis, no data are available on the optimal LGE quantification method.

Methods

Six hundred seventy consecutive patients (48 ± 16 years, 59% male) with suspected myocarditis were enrolled between 2002 and 2015. We performed LGE quantitation using seven different signal intensity thresholding methods based either on 2, 3, 4, 5, 6, 7 standard deviations (SD) above remote myocardium or full width at half maximum (FWHM). In addition, a LGE visual presence score (LGE-VPS) (LGE present/absent in each segment) was assessed. For each of these methods, the strength of association of LGE results with major adverse cardiac events (MACE) was determined. Inter-and intra-rater variability using intraclass-correlation coefficient (ICC) was performed for all methods.

Results

Ninety-eight (15%) patients experienced a MACE at a medium follow-up of 4.7 years. LGE quantification by FWHM, 2- and 3-SD demonstrated univariable association with MACE (hazard ratio [HR] 1.05, 95% confidence interval [CI]:1.02–1.08, p = 0.001; HR 1.02, 95%CI:1.00–1.04; p = 0.001; HR 1.02, 95%CI: 1.00–1.05, p = 0.035, respectively), whereas 4-SD through 7-SD methods did not reach significant association. LGE-VPS also demonstrated association with MACE (HR 1.09, 95%CI: 1.04–1.15, p < 0.001). In the multivariable model, FWHM, 2-SD methods, and LGE-VPS each demonstrated significant association with MACE adjusted to age, sex, BMI and LVEF (adjusted HR of 1.04, 1.02, and 1.07; p = 0.009, p = 0.035; and p = 0.005, respectively). In these, FWHM and LGE-VPS had the highest degrees of inter and intra-rater reproducibility based on their high ICC values.

Conclusions

FWHM is the optimal semi-automated quantification method in risk-stratifying patients with suspected myocarditis, demonstrating the strongest association with MACE and the highest technical consistency. Visual LGE scoring is a reliable alternative method and is associated with a comparable association with MACE and reproducibility in these patients.

Trial registration number

NCT03470571. Registered 13th March 2018. Retrospectively registered.
Literature
2.
go back to reference Grun S, Schumm J, Greulich S, et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol. 2012;59(18):1604–15.PubMedCrossRef Grun S, Schumm J, Greulich S, et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol. 2012;59(18):1604–15.PubMedCrossRef
3.
go back to reference Nakagawa M, Sato A, Okagawa H, Kondo M, Okuno M, Takamatsu T. Detection and evaluation of asymptomatic myocarditis in schoolchildren: report of four cases. Chest. 1999;116(2):340–5.PubMedCrossRef Nakagawa M, Sato A, Okagawa H, Kondo M, Okuno M, Takamatsu T. Detection and evaluation of asymptomatic myocarditis in schoolchildren: report of four cases. Chest. 1999;116(2):340–5.PubMedCrossRef
4.
go back to reference Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the heart failure Association of the European Society of cardiology. J Am Coll Cardiol. 2007;50(19):1914–31.CrossRefPubMed Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the heart failure Association of the European Society of cardiology. J Am Coll Cardiol. 2007;50(19):1914–31.CrossRefPubMed
5.
go back to reference Lurz P, Luecke C, Eitel I, et al. Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: The MyoRacer-Trial. J Am Coll Cardiol. 2016;67(15):1800–11.PubMedCrossRef Lurz P, Luecke C, Eitel I, et al. Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: The MyoRacer-Trial. J Am Coll Cardiol. 2016;67(15):1800–11.PubMedCrossRef
6.
go back to reference Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53(17):1475–87.PubMedPubMedCentralCrossRef Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53(17):1475–87.PubMedPubMedCentralCrossRef
7.
go back to reference Abdel-Aty H, Boye P, Zagrosek A, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005;45(11):1815–22.CrossRefPubMed Abdel-Aty H, Boye P, Zagrosek A, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005;45(11):1815–22.CrossRefPubMed
8.
go back to reference Schumm J, Greulich S, Wagner A, et al. Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. J Cardiovasc Magn Reson. 2014;16:14.PubMedPubMedCentralCrossRef Schumm J, Greulich S, Wagner A, et al. Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. J Cardiovasc Magn Reson. 2014;16:14.PubMedPubMedCentralCrossRef
9.
go back to reference Grani C, Eichhorn C, Biere L, et al. Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. J Am Coll Cardiol. 2017;70(16):1964–76.PubMedCrossRefPubMedCentral Grani C, Eichhorn C, Biere L, et al. Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. J Am Coll Cardiol. 2017;70(16):1964–76.PubMedCrossRefPubMedCentral
10.
11.
go back to reference Templin C, Ghadri JR, Diekmann J, et al. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373(10):929–38.PubMedCrossRef Templin C, Ghadri JR, Diekmann J, et al. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373(10):929–38.PubMedCrossRef
12.
go back to reference Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson. 2013;15:91.PubMedPubMedCentralCrossRef Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson. 2013;15:91.PubMedPubMedCentralCrossRef
13.
go back to reference Flett AS, Hasleton J, Cook C, et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging. 2011;4(2):150–6.PubMedCrossRef Flett AS, Hasleton J, Cook C, et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging. 2011;4(2):150–6.PubMedCrossRef
14.
go back to reference Neilan TG, Coelho-Filho OR, Danik SB, et al. CMR quantification of myocardial scar provides additive prognostic information in nonischemic cardiomyopathy. JACC Cardiovasc Imaging. 2013;6(9):944–54.PubMedPubMedCentralCrossRef Neilan TG, Coelho-Filho OR, Danik SB, et al. CMR quantification of myocardial scar provides additive prognostic information in nonischemic cardiomyopathy. JACC Cardiovasc Imaging. 2013;6(9):944–54.PubMedPubMedCentralCrossRef
15.
go back to reference Amado LC, Gerber BL, Gupta SN, et al. Accurate and objective infarct sizing by contrast-enhanced magnetic resonance imaging in a canine myocardial infarction model. J Am Coll Cardiol. 2004;44(12):2383–9.PubMedCrossRef Amado LC, Gerber BL, Gupta SN, et al. Accurate and objective infarct sizing by contrast-enhanced magnetic resonance imaging in a canine myocardial infarction model. J Am Coll Cardiol. 2004;44(12):2383–9.PubMedCrossRef
16.
go back to reference Zannad F, Stough WG, Pitt B, et al. Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. Eur Heart J. 2008;29(3):413–21.PubMedCrossRef Zannad F, Stough WG, Pitt B, et al. Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. Eur Heart J. 2008;29(3):413–21.PubMedCrossRef
17.
go back to reference Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200.
18.
go back to reference Mikami Y, Kolman L, Joncas SX, et al. Accuracy and reproducibility of semi-automated late gadolinium enhancement quantification techniques in patients with hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2014;16:85.PubMedPubMedCentralCrossRef Mikami Y, Kolman L, Joncas SX, et al. Accuracy and reproducibility of semi-automated late gadolinium enhancement quantification techniques in patients with hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2014;16:85.PubMedPubMedCentralCrossRef
19.
go back to reference Funada A, Kanzaki H, Noguchi T, et al. Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction. Heart Vessel. 2016;31(5):758–70.CrossRef Funada A, Kanzaki H, Noguchi T, et al. Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction. Heart Vessel. 2016;31(5):758–70.CrossRef
20.
go back to reference Alexandre J, Saloux E, Dugue AE, et al. Scar extent evaluated by late gadolinium enhancement CMR: a powerful predictor of long term appropriate ICD therapy in patients with coronary artery disease. J Cardiovasc Magn Reson. 2013;15:12.PubMedPubMedCentralCrossRef Alexandre J, Saloux E, Dugue AE, et al. Scar extent evaluated by late gadolinium enhancement CMR: a powerful predictor of long term appropriate ICD therapy in patients with coronary artery disease. J Cardiovasc Magn Reson. 2013;15:12.PubMedPubMedCentralCrossRef
21.
go back to reference Kancharla K, Weissman G, Elagha AA, et al. Scar quantification by cardiovascular magnetic resonance as an independent predictor of long-term survival in patients with ischemic heart failure treated by coronary artery bypass graft surgery. J Cardiovasc Magn Reson. 2016;18(1):45.PubMedPubMedCentralCrossRef Kancharla K, Weissman G, Elagha AA, et al. Scar quantification by cardiovascular magnetic resonance as an independent predictor of long-term survival in patients with ischemic heart failure treated by coronary artery bypass graft surgery. J Cardiovasc Magn Reson. 2016;18(1):45.PubMedPubMedCentralCrossRef
22.
go back to reference Scott PA, Rosengarten JA, Murday DC, et al. Left ventricular scar burden specifies the potential for ventricular arrhythmogenesis: an LGE-CMR study. J Cardiovasc Electrophysiol. 2013;24(4):430–6.PubMedCrossRef Scott PA, Rosengarten JA, Murday DC, et al. Left ventricular scar burden specifies the potential for ventricular arrhythmogenesis: an LGE-CMR study. J Cardiovasc Electrophysiol. 2013;24(4):430–6.PubMedCrossRef
23.
go back to reference Beek AM, Bondarenko O, Afsharzada F, van Rossum AC. Quantification of late gadolinium enhanced CMR in viability assessment in chronic ischemic heart disease: a comparison to functional outcome. J Cardiovasc Magn Reson. 2009;11:6.PubMedPubMedCentralCrossRef Beek AM, Bondarenko O, Afsharzada F, van Rossum AC. Quantification of late gadolinium enhanced CMR in viability assessment in chronic ischemic heart disease: a comparison to functional outcome. J Cardiovasc Magn Reson. 2009;11:6.PubMedPubMedCentralCrossRef
24.
go back to reference Bondarenko O, Beek AM, Hofman MB, et al. Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson. 2005;7(2):481–5.PubMedCrossRef Bondarenko O, Beek AM, Hofman MB, et al. Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson. 2005;7(2):481–5.PubMedCrossRef
25.
go back to reference Zhang L, Huttin O, Marie PY, et al. Myocardial infarct sizing by late gadolinium-enhanced MRI: comparison of manual, full-width at half-maximum, and n-standard deviation methods. J Magn Reson Imaging. 2016;44(5):1206–17.PubMedCrossRef Zhang L, Huttin O, Marie PY, et al. Myocardial infarct sizing by late gadolinium-enhanced MRI: comparison of manual, full-width at half-maximum, and n-standard deviation methods. J Magn Reson Imaging. 2016;44(5):1206–17.PubMedCrossRef
26.
go back to reference Mewton N, Dernis A, Bresson D, et al. Myocardial biomarkers and delayed enhanced cardiac magnetic resonance relationship in clinically suspected myocarditis and insight on clinical outcome. J Cardiovasc Med (Hagerstown). 2015;16(10):696–703.CrossRef Mewton N, Dernis A, Bresson D, et al. Myocardial biomarkers and delayed enhanced cardiac magnetic resonance relationship in clinically suspected myocarditis and insight on clinical outcome. J Cardiovasc Med (Hagerstown). 2015;16(10):696–703.CrossRef
27.
go back to reference Barone-Rochette G, Augier C, Rodiere M, et al. Potentially simple score of late gadolinium enhancement cardiac MR in acute myocarditis outcome. J Magn Reson Imaging. 2014;40(6):1347–54.PubMedCrossRef Barone-Rochette G, Augier C, Rodiere M, et al. Potentially simple score of late gadolinium enhancement cardiac MR in acute myocarditis outcome. J Magn Reson Imaging. 2014;40(6):1347–54.PubMedCrossRef
28.
go back to reference Khan JN, Nazir SA, Horsfield MA, et al. Comparison of semi-automated methods to quantify infarct size and area at risk by cardiovascular magnetic resonance imaging at 1.5T and 3.0T field strengths. BMC Res Notes. 2015;8:52.PubMedPubMedCentralCrossRef Khan JN, Nazir SA, Horsfield MA, et al. Comparison of semi-automated methods to quantify infarct size and area at risk by cardiovascular magnetic resonance imaging at 1.5T and 3.0T field strengths. BMC Res Notes. 2015;8:52.PubMedPubMedCentralCrossRef
29.
go back to reference McAlindon E, Pufulete M, Lawton C, Angelini GD, Bucciarelli-Ducci C. Quantification of infarct size and myocardium at risk: evaluation of different techniques and its implications. Eur Heart J Cardiovasc Imaging. 2015;16(7):738–46.PubMedPubMedCentralCrossRef McAlindon E, Pufulete M, Lawton C, Angelini GD, Bucciarelli-Ducci C. Quantification of infarct size and myocardium at risk: evaluation of different techniques and its implications. Eur Heart J Cardiovasc Imaging. 2015;16(7):738–46.PubMedPubMedCentralCrossRef
30.
go back to reference Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006;114(15):1581–90.PubMedCrossRef Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006;114(15):1581–90.PubMedCrossRef
Metadata
Title
Comparison of myocardial fibrosis quantification methods by cardiovascular magnetic resonance imaging for risk stratification of patients with suspected myocarditis
Authors
Christoph Gräni
Christian Eichhorn
Loïc Bière
Kyoichi Kaneko
Venkatesh L. Murthy
Vikram Agarwal
Ayaz Aghayev
Michael Steigner
Ron Blankstein
Michael Jerosch-Herold
Raymond Y. Kwong
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Cardiovascular Magnetic Resonance / Issue 1/2019
Electronic ISSN: 1532-429X
DOI
https://doi.org/10.1186/s12968-019-0520-0

Other articles of this Issue 1/2019

Journal of Cardiovascular Magnetic Resonance 1/2019 Go to the issue